Target Audience:
The primary target audience for this activity is the amyloidosis center clinical team as well as respective fellows and residents.

Objective:
To provide a forum for discussions of optimal treatment options for outside physicians charged with caring for patients diagnosed with this very complex, repeatedly misdiagnosed and often deadly disease utilizing a multidisciplinary approach.

Faculty/Planning Committee:
Vaishali Sanchorawala, MD, Course Co-Director
John Berk, MD, Course Co-Director
Lisa Mendelson, NP, Course Co-Director
Alexis Doria, Activity Admin
Elizabeth Drury, CME Senior Program Manager
 

Dr. Sanchorawala is an Advisory Board member at Abbvie, Proclara, Regeneron, Caelum, and Janssen. Dr. Sanchorawala also receives royalties from UpToDate. Dr. Berk is a Scientific Advisory Board member for clinical trails at Eidos Therapeutics, Intellia Therapeutics, and Corino Therapeutics. Dr. Berk is also Study Site Investigator at Alnylam Pharmaceuticals, Ionis Pharmaceutical, and Ad hoc scientific consultant at Akcea.

Dr. Sanchorawala, MD plans on discussing unlabeled/investigational uses of a commercial product: Since no drug is approved by the regulatory agency for systemic AL amyloidosis and treatments are adopted from myeloma, off label use of these drugs will be discussed.  Dr. Berk, MD plans on discussing unlabeled/investigational uses of a commercial product: Diflunisal -- an NSAID demonstrated to alter the course of ATTR amyloidosis disease.

Lisa Mendelson has nothing to disclose.

Disclosure Policy:
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.

Accreditation:

In support of improving patientcare, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 52.00 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Disclaimer:
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS.  ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE.  TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS.  IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS.  IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.  IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

© Trustees of Boston University, 2024